Tau-targeting antibody therapies: too late, wrong epitope or wrong target?

doi:10.1038/s41591-021-01465-9

Comment

. 2021 Aug;27(8):1341-1342.

doi: 10.1038/s41591-021-01465-9.

Tau-targeting antibody therapies: too late, wrong epitope or wrong target?

Edwin Jabbari^{1

2}, Karen E Duff^{3

4}

Affiliations

¹ Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. e.jabbari@ucl.ac.uk.
² Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, UK. e.jabbari@ucl.ac.uk.
³ Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA. k.duff@ucl.ac.uk.
⁴ UK Dementia Research Institute, University College London, London, UK. k.duff@ucl.ac.uk.

PMID: 34385709
DOI: 10.1038/s41591-021-01465-9

Comment

Tau-targeting antibody therapies: too late, wrong epitope or wrong target?

Edwin Jabbari et al. Nat Med. 2021 Aug.

. 2021 Aug;27(8):1341-1342.

doi: 10.1038/s41591-021-01465-9.

Authors

Edwin Jabbari^{1

2}, Karen E Duff^{3

4}

Affiliations

¹ Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. e.jabbari@ucl.ac.uk.
² Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, UK. e.jabbari@ucl.ac.uk.
³ Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA. k.duff@ucl.ac.uk.
⁴ UK Dementia Research Institute, University College London, London, UK. k.duff@ucl.ac.uk.

PMID: 34385709
DOI: 10.1038/s41591-021-01465-9

No abstract available

PubMed Disclaimer

Comment on

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.
Höglinger GU, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B, Lon HK, Jin Z, Fisseha N, Budur K, Gold M, Ryman D, Florian H; Arise Investigators. Höglinger GU, et al. Lancet Neurol. 2021 Mar;20(3):182-192. doi: 10.1016/S1474-4422(20)30489-0. Lancet Neurol. 2021. PMID: 33609476 Clinical Trial.
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.
Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O'Gorman J, Haeberlein SB; PASSPORT Study Group. Dam T, et al. Nat Med. 2021 Aug;27(8):1451-1457. doi: 10.1038/s41591-021-01455-x. Epub 2021 Aug 12. Nat Med. 2021. PMID: 34385707 Clinical Trial.

Cited by

Molecular Tweezers: Supramolecular Hosts with Broad-Spectrum Biological Applications.
Shahpasand-Kroner H, Siddique I, Malik R, Linares GR, Ivanova MI, Ichida J, Weil T, Münch J, Sanchez-Garcia E, Klärner FG, Schrader T, Bitan G. Shahpasand-Kroner H, et al. Pharmacol Rev. 2023 Mar;75(2):263-308. doi: 10.1124/pharmrev.122.000654. Epub 2022 Dec 22. Pharmacol Rev. 2023. PMID: 36549866 Free PMC article. Review.
Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment.
Danis C, Dupré E, Zejneli O, Caillierez R, Arrial A, Bégard S, Mortelecque J, Eddarkaoui S, Loyens A, Cantrelle FX, Hanoulle X, Rain JC, Colin M, Buée L, Landrieu I. Danis C, et al. Mol Ther. 2022 Apr 6;30(4):1484-1499. doi: 10.1016/j.ymthe.2022.01.009. Epub 2022 Jan 7. Mol Ther. 2022. PMID: 35007758 Free PMC article.
Disrupting pathologic phase transitions in neurodegeneration.
Hurtle BT, Xie L, Donnelly CJ. Hurtle BT, et al. J Clin Invest. 2023 Jul 3;133(13):e168549. doi: 10.1172/JCI168549. J Clin Invest. 2023. PMID: 37395272 Free PMC article. Review.
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217.
Kovacech B, Cullen NC, Novak P, Hanes J, Kontsekova E, Katina S, Parrak V, Fresser M, Vanbrabant J, Feldman HH, Winblad B, Stoops E, Vanmechelen E, Zilka N. Kovacech B, et al. Alzheimers Res Ther. 2024 Nov 23;16(1):254. doi: 10.1186/s13195-024-01620-7. Alzheimers Res Ther. 2024. PMID: 39580468 Free PMC article. Clinical Trial.
Distinct tau and alpha-synuclein molecular signatures in Alzheimer's disease with and without Lewy bodies and Parkinson's disease with dementia.
van der Gaag BL, Deshayes NAC, Breve JJP, Bol JGJM, Jonker AJ, Hoozemans JJM, Courade JP, van de Berg WDJ. van der Gaag BL, et al. Acta Neuropathol. 2024 Jan 10;147(1):14. doi: 10.1007/s00401-023-02657-y. Acta Neuropathol. 2024. PMID: 38198008 Free PMC article.

See all "Cited by" articles

References

1. Golbe, L. I. & Ohman-Strickland, P. A. Brain 130, 1552–1565 (2007). - DOI
1. Dam, T. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01455-x (2021).
1. Hoglinger, G. U. et al. Lancet Neurol. 20, 182–192 (2021). - DOI
1. Jadhav, S. et al. Acta Neuropathol. Commun. 7, 22 (2019). - DOI
1. Sopko, R. et al. Neurobiol. Dis. 146, 105120 (2020). - DOI

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information

[1] Golbe, L. I. & Ohman-Strickland, P. A. Brain 130, 1552–1565 (2007). - DOI

[2] Golbe, L. I. & Ohman-Strickland, P. A. Brain 130, 1552–1565 (2007). - DOI

[3] Dam, T. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01455-x (2021).

[4] Dam, T. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01455-x (2021).

[5] Hoglinger, G. U. et al. Lancet Neurol. 20, 182–192 (2021). - DOI

[6] Hoglinger, G. U. et al. Lancet Neurol. 20, 182–192 (2021). - DOI

[7] Jadhav, S. et al. Acta Neuropathol. Commun. 7, 22 (2019). - DOI

[8] Jadhav, S. et al. Acta Neuropathol. Commun. 7, 22 (2019). - DOI

[9] Sopko, R. et al. Neurobiol. Dis. 146, 105120 (2020). - DOI

[10] Sopko, R. et al. Neurobiol. Dis. 146, 105120 (2020). - DOI

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Tau-targeting antibody therapies: too late, wrong epitope or wrong target?

Affiliations

Tau-targeting antibody therapies: too late, wrong epitope or wrong target?

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical